Fortress Biotech (FBIO)
(Delayed Data from NSDQ)
$1.97 USD
+0.22 (12.57%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $1.95 -0.02 (-1.02%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Fortress Biotech, Inc. [FBIO]
Reports for Purchase
Showing records 161 - 180 ( 316 total )
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Multiple Catalysts Ahead, Plenty of Cash, Too
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Ximino/Targadox Tracker - Week ending 8/28/2020
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
CUTX-101 Pivotal Data Win; Rolling NDA to Start 4Q20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Ximino/Targadox Tracker - Week ending 8/21/2020
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Ximino/Targadox Tracker - Week ending 8/14/2020
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Results; Looking Toward Significant Potential Cash Flow
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: EU is Positive on CUTX-101 Menke?s Disease
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J